DZ Bank’s Protalix BioTherapeutics PLX Stock Holding History

DZ Bank’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-34,650	Closed	-$187K	–	1030
2018 Q1	$187K	Buy	+34,650	New	+$228K	﹤0.01%	941

Other funds holding PLX

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

MIH

Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

DZ Bank's PLX Position: Q2 2018 in Review

DZ Bank sold out of Protalix BioTherapeutics (PLX) in Q2 2018, closing a stake of 34,650 shares — an estimated $187K sold.

DZ Bank first reported a position in PLX in Q1 2018 and held it in 1 quarter. The position peaked at $187K in Q1 2018. 36 funds tracked by Wall St. Rank hold PLX as of Q2 2018.

DZ Bank reported no remaining Protalix BioTherapeutics position as of Q2 2018 after selling out during the quarter.
DZ Bank sold 34,650 Protalix BioTherapeutics shares in Q2 2018, an estimated $187K.
DZ Bank first reported a position in Protalix BioTherapeutics in Q1 2018 and held it in 1 quarter.
DZ Bank's Protalix BioTherapeutics position peaked at $187K in Q1 2018.
36 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2018.

Based on DZ Bank's 13F filing for Q2 2018, filed 14 Aug 2018.